Radiotherapy Increases Sarcoma Risk in TP53 Breast Cancer

Patients with breast cancer carrying TP53 pathogenic variants have an 8.8% risk of developing sarcoma within 15 years of radiotherapy. The risk of developing any secondary cancer within 10 years was high in TP53 carriers regardless of radiotherapy. A study evaluated 91 patients with TP53 variants, finding 8.8% developed in-field sarcoma after radiotherapy. The risk of secondary cancer over 10 years was 22.5% for those receiving radiotherapy and 38% for those who did not. Overall survival did not differ significantly between the groups. The study emphasizes balancing the iatrogenic risks of radiotherapy with therapeutic benefits for breast cancer patients with TP53 variants.

Source link